You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國醫藥(600056.SH):子公司兩份注射用更昔洛韋通過仿製藥一致性評價
格隆匯 06-21 17:46

格隆匯6月21日丨中國醫藥(600056.SH)公佈,近日,公司下屬子公司湖北科益藥業股份有限公司(“科益藥業”)獲得國家藥監局核准簽發的兩份注射用更昔洛韋(以下簡稱“該藥品”)《藥品補充申請批准通知書》,該藥品通過仿製藥質量和療效一致性評價。

更昔洛韋為核苷類抗病毒藥,具有廣譜、高效抑制皰疹病毒作用,可治療鉅細胞病毒感染,對乙肝病毒和腺病毒亦有較強作用。經查詢國家藥監局網站顯示,截至該公吿披露日,國內生產廠家海南普利製藥股份有限公司、揚子江藥業集團有限公司、武漢普生製藥有限公司已通過該藥品的一致性評價。

截至公吿披露日,該藥品研發費用投入約728.19萬元人民幣(未經審計)。根據第三方數據庫PDB查詢顯示,該藥品2020年國內樣本醫院銷售額約為8643萬元。公司該藥品2020年銷售收入約為4545萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account